Clicky

Intelligence » Pancreatitis » Latest Posts

Subscribe to get latest posts via email or subscribe to a RSS feed.

Tuesday, January 16, 2018 -- Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic cancer.

Thursday, January 04, 2018 -- Use of epidural analgesia in patients with critically acute pancreatitis may reduce the 30-day mortality rates compared with the absence of a pain management strategy.

Wednesday, November 22, 2017 -- by Masaki Miyazawa, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Koichiro Matsuda, Taku Sanada, Takeshi Urabe, Katsuhisa Inamura, Takashi Kagaya, Hideki Mizuno, Uichiro Fuchizaki, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko Background and aim Relapse and diabetes mellitus (DM) are major problems for the prognosis of autoimmune pancreatitis (AIP). We examined the prognosis of type 1 AIP after corticosteroid therapy (CST)-induced remission in terms of relapse and DM. Methods The study enrolled 82 patients diagnosed with type 1 AIP who achieved remission with CST. We retrospectively evaluated the relapse rate in terms of the administration period of CST, clinical factors associated with relapse, and the temporal change in glucose tolerance. Results

Monday, November 20, 2017 -- Radiology, Volume 285, Issue 3, Page 1061-1063, December 2017.

Saturday, November 04, 2017 -- In patients with infected necrotising pancreatitis, the endoscopic step-up approach was not superior to the surgical step-up approach in reducing major complications or death. The rate of pancreatic fistulas and length of hospital stay were lower in the endoscopy group. The outcome of this trial will probably result in a shift to the endoscopic step-up approach as treatment preference.

Wednesday, October 25, 2017 -- AzurRx BioPharma is planning to expand the clinical development of its investigative therapy MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) caused by chronic inflammation of the pancreas and cystic fibrosis (CF) into Europe. The company has submitted an Investigational Medicinal Product Dossier (IMPD) — similar to an Investigational New Drug (IND) application in […] The post AzurRx Seeks to Expand Trial of MS1819 for EPI Caused by CF, Chronic Pancreatitis to Europe appeared first on Cystic Fibrosis News Today.

Monday, October 02, 2017 -- Pancreatitis remains a diagnostic challenge in patients with mild to moderate disease, with current imaging modalities being inadequate. Given the prominent macrophage infiltration in chronic pancreatitis, we hypothesized that 125I-iodo-DPA-713, a small-molecule radiotracer that specifically targets macrophages, could be used with SPECT/CT to image pancreatic inflammation in a relevant experimental model. Methods: Chronic pancreatitis was induced with cerulein in C57BL/6 mice, which were contrasted with saline-injected control mice. The animals were imaged at 7 wk after induction using N,N-diethyl-2-(2-(3-125I-iodo-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (125I-iodo-DPA-713) SPECT/CT or 18F-FDG PET/CT. The biodistribution of 125I-iodo-DPA-713 was determined under the same conditions, and a pair of mice was imaged using a fluorescent analog of 125I-iodo-DPA-713, DPA-713-IRDye800CW, for correlative histology. Results: Pancreatic 125I-iodo-DPA-713 uptake was significantly higher in

Wednesday, September 20, 2017 -- OBJECTIVE Diabetes frequently develops in patients with chronic pancreatitis. We examined the alterations in the glucagon response to hypoglycemia and to oral glucose administration in patients with diabetes due to chronic pancreatitis. RESEARCH DESIGN AND METHODS Ten patients with diabetes secondary to chronic pancreatitis were compared with 13 patients with type 2 diabetes and 10 healthy control subjects. A stepwise hypoglycemic clamp and an oral glucose tolerance test (OGTT) were performed. RESULTS Glucose levels during the OGTT were higher in patients with diabetes and chronic pancreatitis and lower in control subjects (P < 0.0001). Insulin and C-peptide levels were reduced, and the glucose-induced suppression of glucagon was impaired in both groups with diabetes (all P < 0.0001 vs. control

Wednesday, September 20, 2017 -- Many patients with chronic pancreatitis develop diabetes (chronic pancreatitis–related diabetes [CPRD]) through an undetermined mechanism. Here we used long-term partial pancreatic duct ligation (PDL) as a model to study CPRD. We found that long-term PDL induced significant β-cell dedifferentiation, followed by a time-dependent decrease in functional β-cell mass—all specifically in the ligated tail portion of the pancreas (PDL-tail). High levels of transforming growth factor β1 (TGFβ1) were detected in the PDL-tail and were mainly produced by M2 macrophages at the early stage and by activated myofibroblasts at the later stage. Loss of β-cell mass was then found to result from TGFβ1-triggered epithelial-mesenchymal transition (EMT) by β-cells, rather than resulting directly from β-cell apoptosis. Mechanistically, TGFβ1-treated β-cells activated expression of

Monday, September 18, 2017 -- Cypralis, has been awarded funding by Innovate UK to develop cyclophilin inhibitors targeting fibrotic diseases...

Monday, September 04, 2017 -- Furosemide-induced acute pancreatitis can occur several hours to up to 7 weeks after starting treatment.

Wednesday, August 23, 2017 -- Results on First Six Patients Expected in September Company Adds Additional Clinical Trial Site to Further Support Enrollment in this Study and Other Planned Future Studies BROOKLYN, N.Y., Aug. 23, 2017 -- AzurRx...

Monday, August 21, 2017 -- Samsung Bioepis has joined with Takeda to develop multiple novel biologic therapies, including the collaboration’s first therapeutic candidate, TAK-671 for severe acute pancreatitis, according to a press release.“Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in the release. “Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”

Monday, August 14, 2017 -- Furosemide-induced acute pancreatitis can occur several hours to up to 7 weeks after starting treatment; dose may also play a role. This patient, the authors note, fell into the category of "long-term latency" and "low-dosage (40mg)"

Wednesday, August 02, 2017 -- Similarly disturbed α-cell responses to oral glucose ingestion and hypoglycemia

Thursday, July 20, 2017 -- Since the risk of a second asparaginase-associated pancreatitis was not associated with severity of the first asparaginase-associated pancreatitis and a second asparaginase-associated pancreatitis did not involve an increased risk of complications, asparaginase re-exposure should be determined mainly by the anticipated need for asparaginase for antileukaemic efficacy. A study of the genetic risk factors identifying patients in whom asparaginase exposure should be restricted is needed.

Sunday, July 16, 2017 -- Johns Hopkins Medicine surgeons have developed a minimally invasive surgery to address chronic pancreatitis, a painful condition that can be remedied by removing the pancreas. While some cases of chronic pancreatitis are caused by alcoholism, most of them are from a genetic mutation. But the suffers...

Wednesday, July 12, 2017 -- Laparoscopic total pancreatectomy with islet autotransplantation and intraoperative islet separation, a new minimally invasive surgical approach for treating chronic pancreatitis, was successfully completed and improved outcomes in the first 20 patients to undergo the procedure.According to data from the case series published in JAMA Surgery, the approach reduced complications, hospital stays and the need for opioids.

Wednesday, June 21, 2017 -- OBJECTIVE To describe amylase/lipase activity levels and events of acute pancreatitis (AP) in the SCALE (Satiety and Clinical Adiposity—Liraglutide Evidence in individuals with and without diabetes) weight-management trials. RESEARCH DESIGN AND METHODS Secondary analyses were performed on pooled data from four trials (N = 5,358 with BMI ≥30, or 27 to <30 kg/m2 with ≥1 comorbidity). Of these, 1,723 had normoglycemia, 2,789 had prediabetes, and 846 had type 2 diabetes. Participants were randomized to liraglutide 3.0 mg (n = 3,302), liraglutide 1.8 mg (n = 211, only type 2 diabetes), or placebo (n = 1,845). Relationships between baseline characteristics and amylase/lipase activity at baseline and during treatment were investigated. RESULTS Over 56 weeks, liraglutide 3.0 mg versus placebo was

Wednesday, June 21, 2017 -- OBJECTIVE To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3.5–5.0 years. RESEARCH DESIGN AND METHODS A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years). Fasting serum lipase and amylase were monitored. Acute pancreatitis was adjudicated in a blinded manner. RESULTS Compared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively. Levels were increased at 6 months and then remained stable. During the study, 18 (0.4% [1.1 events/1,000 patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5%

Related pages


is bioslim safeवैल्पोरिक एसिड दुष्प्रभाव जिगरnims tablet uses in urduwhat is halobetasol propionate creamvicks cough syrup ingredientshemolokgelsemium usesbroncovitfamilial hypercholesterolemia symptomsmext tabletflax seed spanishcodeine insomnialaxoberon side effectsoseltamivir side effectssimethicone side effectsbetnovate cl ointmentvernace tabletvoltic tabletprothiyaden M tablet usage in hindigotu kola reviewsuses for aquamarinecardace 5 side effectsdefcort side effectstenbetanoro ellipta inhalertaxim injection uses in hindisqualane oil benefitsparacetamol suppository side effectsbengay and breastfeedingpaludrine side effectshistac side effectsevion cream usagepill cr 500onabet creamcalpol tabletforcidadrenochromewhat is cal mag used forparaparesis causesano ang desertsucralcoatorly tabletsheart savior reviewsmanganese dioxide usesis zerodol a painkilleriszupodowart medicinerabiwok dsr tabletbroncolin reviewspolicosanol benefitshibitane antisepticclindamycin gel usesgard shampooisopropyl alcohol adalahtablets for toothachezebinix side effectssynocromwhere can i buy betadine ointmentcombiflam tablet for whatalbuterol ingredientszeegut p medicinehalovate f cream usestrihemic side effectsberotec inhalerwhat is ciclopirox gel 0.77 used forclomipure 50 mg tabletskremil stydol 50 tableteptoin actionhow to use otrivintrexan medicationneurobion indonesiasoframycin skin cream usessyndol tablets for saleparamount tabletbetnesoltablet dexatopicort side effectsasthalin syrup for infantscan you overdose on guaifenesinicpa health productshyoscyamine indicationsआर बी टोनwhat does e45 do